Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant

This study analysed the outcome of 563 Aplastic Anaemia (AA) children aged 0–12 years reported to the Severe Aplastic Anaemia Working Party database of the European Society for Blood and Marrow Transplantation, according to treatment received. Overall survival (OS) after upfront human leucocyte antigen‐matched family donor (MFD) haematopoietic stem cell transplantation (HSCT) or immunosuppressive treatment (IST) was 91% vs. 87% (P 0·18). Event‐free survival (EFS) after upfront MFD HSCT or IST was 87% vs. 33% (P 0·001). Ninety‐one of 167 patients (55%) failed front‐line IST and underwent rescue HSCT. The OS of this rescue group was 83% compared with 91% for upfront MFD HSCT patients and 97% for those who did not fail IST up‐front (P 0·017). Rejection was 2% for MFD HSCT and HSCT post‐IST failure (P 0·73). Acute graft‐versus‐host disease (GVHD) grade II‐IV was 8% in MFD graft vs. 25% for HSCT post‐IST failure (P < 0·0001). Chronic GVHD was 6% in MFD HSCT vs. 20% in HSCT post‐IST failure (P < 0·0001). MFD HSCT is an excellent therapy for children with AA. IST has a high failure rate, but remains a reasonable first‐line choice if MFD HSCT is not available because high OS enables access to HSCT, which is a very good rescue option.

[1]  R. Suzuki,et al.  First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy , 2014, Haematologica.

[2]  M. Aljurf,et al.  Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation , 2014, Haematologica.

[3]  S. Samarasinghe,et al.  Immune suppression for childhood acquired aplastic anemia and myelodysplastic syndrome: where next? , 2014, Haematologica.

[4]  S. Kojima,et al.  Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children , 2014, Haematologica.

[5]  A. Bacigalupo,et al.  Front-line immunosuppressive treatment of acquired aplastic anemia , 2013, Bone Marrow Transplantation.

[6]  N. Young,et al.  How I treat acquired aplastic anemia. , 2012, Blood.

[7]  G. Mufti,et al.  Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. , 2012, Blood.

[8]  P. Veys,et al.  Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience , 2012, British journal of haematology.

[9]  S. Samarasinghe,et al.  How I manage aplastic anaemia in children , 2012, British journal of haematology.

[10]  M. Aljurf,et al.  Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups , 2012, Haematologica.

[11]  J. Fay,et al.  Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. , 2011, Blood.

[12]  G. Mufti,et al.  Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. , 2011, Blood.

[13]  N. Young,et al.  Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. , 2011, The New England journal of medicine.

[14]  T. Nakahata,et al.  Predicting response to immunosuppressive therapy in childhood aplastic anemia , 2011, Haematologica.

[15]  V. Pistoia,et al.  Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia , 2009, Haematologica.

[16]  J. Cavenagh,et al.  Guidelines for the diagnosis and management of aplastic anaemia , 2009, British journal of haematology.

[17]  F. Bessho,et al.  Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. , 2008, Blood.

[18]  J. Klein,et al.  Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. , 2007, Blood.

[19]  R. Krance,et al.  Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  N. Young,et al.  Current concepts in the pathophysiology and treatment of aplastic anemia. , 2006, Blood.

[21]  N. Young,et al.  Retreatment with rabbit anti‐thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia , 2006, British journal of haematology.

[22]  W. Friedrich,et al.  Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. , 2005, Blood.

[23]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[24]  F. Rodeghiero,et al.  Rabbit antithymocyte globulin (r‐ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy , 1999, British journal of haematology.

[25]  F. Frassoni,et al.  The assessment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia , 1998 .

[26]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[27]  K. Aoki.  [Epidemiology of aplastic anemia]. , 1978, Nihon rinsho. Japanese journal of clinical medicine.

[28]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  S. Samarasinghe,et al.  Management of Acquired Aplastic Anemia in Children , 2017 .

[31]  S. Eustace,et al.  Bone Marrow , 2004 .

[32]  F. Frassoni,et al.  The assessment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia. , 1998, Blood.

[33]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .